Literature DB >> 1908883

Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions.

I Sanz1.   

Abstract

The area of highest variability in the antibody-combining site is the third complementarity determining region or CDR3. Based on our preliminary observation of the tremendous variability of this region in the human system we have studied the potential of CDR3 regions for generating diversity in the human B cell repertoire. To this end we generated CDR3-specific cDNA libraries from tissues collected at several stages of human development. Detailed computer analysis of more than 500 sequences reveals that human CDR3 region have the potential to generate more than 10(14) different peptides. The mechanisms responsible for this diversity include rearrangement by inversion, D-D fusion, gene conversion and the frequent utilization of the recently described DIR genes. The specific recombination mechanisms which may explain aberrant rearrangements as well as differences between fetal and adult repertoires are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908883

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

1.  Rheumatoid factors in primary Sjögren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation.

Authors:  K E Elagib; M Børretzen; R Jonsson; H J Haga; J Thoen; K M Thompson; J B Natvig
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B.

Authors:  Y Sun; M K Park; J Kim; B Diamond; A Solomon; M H Nahm
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

Review 3.  Regulation and chance in the ontogeny of B and T cell antigen receptor repertoires.

Authors:  Michael Zemlin; Robert L Schelonka; Karl Bauer; Harry W Schroeder
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift.

Authors:  J M Bye; C Carter; Y Cui; B D Gorick; S Songsivilai; G Winter; N C Hughes-Jones; J D Marks
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

6.  Somatic diversification in the heavy chain variable region genes expressed by human autoantibodies bearing a lupus-associated nephritogenic anti-DNA idiotype.

Authors:  C Demaison; P Chastagner; J Thèze; M Zouali
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

7.  Identification of the V genes encoding xenoantibodies in non-immunosuppressed rhesus monkeys.

Authors:  Annette Kleihauer; Clare R Gregory; Dominic C Borie; Andrew E Kyles; Irina Shulkin; Insiyyah Patanwala; Joanne Zahorsky-Reeves; Vaughn A Starnes; Yoko Mullen; Ivan T Todorov; Mary Kearns-Jonker
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

8.  Clustered Mutations at the Murine and Human IgH Locus Exhibit Significant Linkage Consistent with Templated Mutagenesis.

Authors:  Gordon A Dale; Daniel J Wilkins; Caitlin D Bohannon; Dario Dilernia; Eric Hunter; Trevor Bedford; Rustom Antia; Ignacio Sanz; Joshy Jacob
Journal:  J Immunol       Date:  2019-08-02       Impact factor: 5.422

9.  Comparable profiles of the immunoglobulin heavy chain complementarity determining region (CDR)-3 in CD5+ and CD5- human cord blood B lymphocytes.

Authors:  H Kiyoi; K Naito; R Ohno; T Naoe
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

Review 10.  The molecular structure of human antibodies specific for the human immunodeficiency virus.

Authors:  J S Andris; J D Capra
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.